Last $6.55 USD
Change Today -0.05 / -0.76%
Volume 312.9K
As of 8:10 PM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

northwest biotherapeutics (NWBO) Snapshot

Open
$6.58
Previous Close
$6.60
Day High
$6.71
Day Low
$6.40
52 Week High
03/11/14 - $10.64
52 Week Low
11/6/13 - $3.10
Market Cap
374.6M
Average Volume 10 Days
348.0K
EPS TTM
$-1.95
Shares Outstanding
57.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NORTHWEST BIOTHERAPEUTICS (NWBO)

Related News

No related news articles were found.

northwest biotherapeutics (NWBO) Related Businessweek News

No Related Businessweek News Found

northwest biotherapeutics (NWBO) Details

Northwest Biotherapeutics, Inc., a development stage biotechnology company, discovers and develops immunotherapy products to treat cancers in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. The company’s products include DCVax-L, which is under Phase III brain cancer trial for treating brain and ovarian cancer; DCVax-Direct that is under Phase I/II clinical for various types of inoperable solid tumor cancers; and DCVax-Prostate for late stage hormone independent prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

9 Employees
Last Reported Date: 04/1/14
Founded in 1996

northwest biotherapeutics (NWBO) Top Compensated Officers

Chairperson, Chief Executive Officer, Preside...
Total Annual Compensation: $360.0K
Founder, Chief Scientific Officer, Secretary ...
Total Annual Compensation: $295.7K
Senior Vice President of Clinical Research
Total Annual Compensation: $300.0K
Chief Technical Officer
Total Annual Compensation: $325.2K
Senior Vice President of Business Development
Total Annual Compensation: $348.0K
Compensation as of Fiscal Year 2013.

northwest biotherapeutics (NWBO) Key Developments

Northwest Biotherapeutics, Inc. Announces Completion of DCVax(R)-Direct Phase I Trial Recruitment

Northwest Biotherapeutics, Inc. announced that the Phase I portion of the company's Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment and the company is now underway with preparations for the Phase II portion of this trial, as well as expansion of DCVax-Direct manufacturing. The Phase I/II trial is testing the safety and activity of DCVax-Direct in various types of cancer. The Phase I portion of the trial has involved testing of 3 different dose levels, and a diverse range of cancers. The patients enrolled in Phase I will continue to receive treatments in accordance with the protocol. With the closing of Phase I, the company is now preparing to initiate the Phase II portion of the trial. This second part of the Phase I/II study will target 24 or more patients in selected cancers. Additional trial sites are being brought on to facilitate and expedite enrollment.

Northwest Biotherapeutics, Inc.(NasdaqCM:NWBO) added to Russell 2000 Index

Northwest Biotherapeutics, Inc. will be added to the Russell 2000 Index.

Northwest Biotherapeutics, Inc.(NasdaqCM:NWBO) added to Russell 3000 Index

Northwest Biotherapeutics, Inc. will be added to the Russell 3000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NWBO:US $6.55 USD -0.05

NWBO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NWBO.
View Industry Companies
 

Industry Analysis

NWBO

Industry Average

Valuation NWBO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 514.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 541.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NORTHWEST BIOTHERAPEUTICS, please visit www.nwbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.